Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus compared with Advagraf in de novo liver transplant recipients (EnGraft)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary) ; Tacrolimus
Indications Liver transplant rejection
Focus Pharmacokinetics
Acronyms EnGraft Study

Most Recent Events

13 Feb 2024 Planned End Date changed from 1 Sep 2026 to 1 Oct 2026.
13 Feb 2024 Status changed from recruiting to active, no longer recruiting.
10 May 2023 Planned End Date changed from 1 Jun 2026 to 1 Sep 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight